{"id":745283,"date":"2016-12-16T07:26:00","date_gmt":"2016-12-16T07:26:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/"},"modified":"2025-11-07T01:25:27","modified_gmt":"2025-11-07T06:25:27","slug":"european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/","title":{"rendered":"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor&#8230;"},"content":{"rendered":"<p class=\"bwalignc\">       Opinion Based on Findings from KEYNOTE-024 Trial, Which Showed        Superior Overall Survival and Progression Free Survival with KEYTRUDA        Compared to Chemotherapy     <\/p>\n<p class=\"bwalignc\">       First Anti-PD-1 Therapy to Receive a CHMP Positive Opinion for        Previously Untreated Patients with Metastatic NSCLC     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the Committee for Medicinal Products for Human Use<br \/>\n      (CHMP) of the European Medicines Agency (EMA) has adopted a positive<br \/>\n      opinion recommending approval of KEYTRUDA\u00ae (pembrolizumab), the<br \/>\n      company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic<br \/>\n      non-small cell lung cancer (NSCLC) in adults whose tumors have high<br \/>\n      PD-L1 expression (tumor proportion score [TPS] of 50 percent or more)<br \/>\n      with no EGFR or ALK positive tumor mutations. The recommendation will<br \/>\n      now be reviewed by the European Commission for marketing authorization<br \/>\n      in the European Union. A final decision is expected in the first quarter<br \/>\n      of 2017. KEYTRUDA is currently approved in Europe for the second-line<br \/>\n      treatment of patients with locally advanced or metastatic NSCLC whose<br \/>\n      tumors express PD-L1 and who have received at least one prior<br \/>\n      chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations<br \/>\n      should also have received targeted therapy before receiving KEYTRUDA.\n    <\/p>\n<p>\n      \u201cLung cancer is one of the leading causes of death in the EU, so today\u2019s<br \/>\n      news is an important step forward for many patients in Europe. If<br \/>\n      approved, patients with metastatic non-small cell lung cancer with high<br \/>\n      PD-L1 expression could receive KEYTRUDA instead of chemotherapy as their<br \/>\n      initial treatment,\u201d said Dr. Roger Dansey, senior vice president and<br \/>\n      therapeutic area head, oncology late-stage development, Merck Research<br \/>\n      Laboratories. \u201cWe are committed to working collaboratively with<br \/>\n      governments and other stakeholders to ensure that KEYTRUDA will be made<br \/>\n      available to patients in Europe as quickly as possible.\u201d\n    <\/p>\n<p>\n      The positive opinion is based on data from KEYNOTE-024, a pivotal study<br \/>\n      which demonstrated superior overall survival and progression-free<br \/>\n      survival with KEYTRUDA (pembrolizumab) compared to chemotherapy in<br \/>\n      patients whose tumors expressed high levels of PD-L1 with no EGFR or ALK<br \/>\n      positive tumor mutations.\n    <\/p>\n<p>\n      KEYNOTE-024 is a randomized, open-label, phase 3 study evaluating<br \/>\n      KEYTRUDA monotherapy at a fixed dose of 200 mg compared to standard of<br \/>\n      care platinum-containing chemotherapy for the treatment of patients with<br \/>\n      both squamous and non-squamous metastatic NSCLC. The study enrolled<br \/>\n      patients who had not received prior systemic chemotherapy treatment for<br \/>\n      their metastatic disease and whose tumors had high PD-L1 expression with<br \/>\n      no EGFR or ALK aberrations.\n    <\/p>\n<p>\n      <b>About Lung Cancer<\/b>\n    <\/p>\n<p>\n      Lung cancer, which forms in the tissues of the lungs, usually within<br \/>\n      cells lining the air passages, is the leading cause of cancer death<br \/>\n      worldwide. Each year, more people die of lung cancer than die of colon,<br \/>\n      breast, and prostate cancers combined. The two main types of lung cancer<br \/>\n      are non-small cell and small cell. NSCLC is the most common type of lung<br \/>\n      cancer, accounting for about 85 percent of all cases. The five-year<br \/>\n      survival rate for patients suffering from highly advanced, metastatic<br \/>\n      (Stage IV) lung cancers is estimated to be two percent.\n    <\/p>\n<p>\n      <b>About KEYTRUDA\u00ae (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b> <b>Indications and Dosing in the U.S.<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      unresectable or metastatic melanoma at a dose of 2 mg\/kg every three<br \/>\n      weeks until disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the first-line treatment of patients with<br \/>\n      metastatic non-small cell lung cancer (NSCLC) whose tumors have high<br \/>\n      PD-L1 expression [tumor proportion score (TPS) \u226550%] as determined by an<br \/>\n      FDA-approved test, with no EGFR or ALK genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with metastatic<br \/>\n      NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined by an<br \/>\n      FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA\u00ae<\/b>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA (pembrolizumab) for Grade 2; permanently discontinue<br \/>\n      KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. For suspected immune-mediated adverse reactions, ensure<br \/>\n      adequate evaluation to confirm etiology or exclude other causes. Based<br \/>\n      on the severity of the adverse reaction, withhold KEYTRUDA and<br \/>\n      administer corticosteroids. Upon improvement to Grade 1 or less,<br \/>\n      initiate corticosteroid taper and continue to taper over at least 1<br \/>\n      month. Based on limited data from clinical studies in patients whose<br \/>\n      immune-related adverse reactions could not be controlled with<br \/>\n      corticosteroid use, administration of other systemic immunosuppressants<br \/>\n      can be considered. Resume KEYTRUDA when the adverse reaction remains at<br \/>\n      Grade 1 or less following corticosteroid taper. Permanently discontinue<br \/>\n      KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs<br \/>\n      and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for signs and symptoms of infusion-related reactions,<br \/>\n      including rigors, chills, wheezing, pruritus, flushing, rash,<br \/>\n      hypotension, hypoxemia, and fever. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 8% of 682 patients<br \/>\n      with metastatic NSCLC. The most common adverse event resulting in<br \/>\n      permanent discontinuation of KEYTRUDA was pneumonitis (1.8%). Adverse<br \/>\n      reactions leading to interruption of KEYTRUDA occurred in 23% of<br \/>\n      patients; the most common (\u22651%) were diarrhea (1%), fatigue (1.3%),<br \/>\n      pneumonia (1%), liver enzyme elevation (1.2%), decreased appetite<br \/>\n      (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA (pembrolizumab) is excreted in human<br \/>\n      milk. Because many drugs are excreted in human milk, instruct women to<br \/>\n      discontinue nursing during treatment with KEYTRUDA and for 4 months<br \/>\n      after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes nearly 400 clinical trials evaluating our<br \/>\n      anti-PD-1 therapy across more than 30 tumor types. We also continue to<br \/>\n      strengthen our immuno-oncology portfolio through strategic acquisitions<br \/>\n      and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=a39677ea7f2995cff048bc711fcd2966\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=b730f46469f7aae9a534c23b11617ab0\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=35715bb742c488ffa6fa1f493dd938ae\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=3a2b00b421eb9b9788d7f8d1dfa1f909\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=4639d1dbacf1f569506c4fe1ae55f57a\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=13b7bc596dab6a743077d0d386225590\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=5d248cd3798d7867a419a252bb7ada93\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=085136a429ed5957f3eee8bc4686a961\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<br \/>\n      Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51478400&amp;newsitemid=20161216005267&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=e3172c3ee0d2dee4a14cad7e1da1f3e0\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161216005267r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. The recommendation will now be reviewed by the European Commission for marketing authorization in the European Union. A final decision is expected in the first quarter of 2017. KEYTRUDA is currently approved in Europe for the second-line treatment of patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745283","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor... - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor... - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. The recommendation will now be reviewed by the European Commission for marketing authorization in the European Union. A final decision is expected in the first quarter of 2017. KEYTRUDA is currently approved in Europe for the second-line treatment of patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\\\/\",\"name\":\"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor... - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-12-16T07:26:00+00:00\",\"dateModified\":\"2025-11-07T06:25:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor&#8230;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor... - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/","og_locale":"en_US","og_type":"article","og_title":"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor... - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK positive tumor mutations. The recommendation will now be reviewed by the European Commission for marketing authorization in the European Union. A final decision is expected in the first quarter of 2017. KEYTRUDA is currently approved in Europe for the second-line treatment of patients with locally advanced or metastatic NSCLC whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumor mutations should also have received","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:27+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/","name":"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor... - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-12-16T07:26:00+00:00","dateModified":"2025-11-07T06:25:27+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/european-medicines-agencys-chmp-recommends-mercks-keytruda-pembrolizumab-for-the-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"European Medicines Agency\u2019s CHMP Recommends Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor&#8230;"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"81bab320-ac3a-48eb-ba52-f4d6fd7e3c9c","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/European-Medicines-Agencys-CHMP-Recommends-Mercks-KEYTRUDA-pembrolizumab-for-the-First-Line-Treatment-of-Patients-with-Metastatic-Non-2KDQK.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745283\/revisions"}],"predecessor-version":[{"id":3674698,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745283\/revisions\/3674698"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745283"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}